Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 11—November 2022
Research Letter

Serologic Evidence of Human Exposure to Ehrlichiosis Agents in Japan

Hongru Su, Kenji Kubo, Shigetoshi Sakabe, Shinsuke Mizuno, Nobuhiro Komiya, Shigehiro Akachi, Hiromi Fujita1, Kozue Sato, Hiroki Kawabata, Hiromi Nagaoka, Shuji Ando, and Norio OhashiComments to Author 
Author affiliations: University of Shizuoka, Shizuoka, Japan (H. Su, N. Ohashi); Japanese Red Cross Wakayama Medical Center, Wakayama, Japan (K. Kubo, S. Mizuno, N. Komiya); Ise Red Cross Hospital, Ise, Japan (S. Sakabe); Mie Prefecture Health and Environment Research Institute, Yokkaichi, Japan (S. Akachi); Mahara Institute of Medical Acarology, Anan, Japan (H. Fujita); National Institute of Infectious Diseases, Tokyo, Japan (K. Sato, H. Kawabata, S. Ando); Shizuoka Institute of Environment and Hygiene, Shizuoka (H. Nagaoka)

Main Article

Table

Evaluation of immunofluorescence assay titers and Western blots of serum samples from 3 febrile patients demonstrating serologic evidence of human exposure to ehrlichiosis agents in Japan*

Case no. (year) No. days† Ehrlichia chaffeensis antigens, IgM/IgG
 Anaplasma phagocytophilum antigens, IgM/IgG
IFA, THP-1 cells Western blot
 IFA
 Western blot, THP-1 cells
DH82 cells THP-1 cells THP-1 cells HL60 cells
1 (2015) 2 20/160 −/+ −/− <20/<20 <20/<20 −/−
17 80/640 +/+ +/+ <20/<20 <20/<20 −/−
2 (2018) 14 20/20 +/+ +/+ <20/<20 <20/<20 −/−
32 40/320 +/+ +/+ <20/<20 <20/<20 −/−
60 20/20 +/+ +/+ <20/<20 <20/<20 −/−
3 (2018) 5 20/20 +/+ +/+ <20/40 <20/20 −/+
58 80/80 +/+ +/+ <20/40 <20/40 −/+
115 20/320 +/+ +/+ <20/40 <20/40 −/+

*Serum samples were collected from 3 patients in Japan in 2015 and 2018 and assayed by using THP-1, DH82, or HL60 cells infected with E. chaffeensis or A. phagocytophilum. Western blots were categorized as positive or negative for IgM and IgG against antigens from each bacterial species. IFA, immunofluorescence assay. †No. days after onset of illness.

Main Article

1Current affiliation: Northern Fukushima Medical Center, Date, Japan.

Page created: September 08, 2022
Page updated: October 24, 2022
Page reviewed: October 24, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external